Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7645 USD | -5.95% | +2.80% | -62.52% |
Apr. 15 | Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform | CI |
Apr. 02 | Top Midday Decliners | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.52% | 81.34M | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.76% | 29.48B | |
+56.72% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+5.17% | 8.75B |
- Stock Market
- Equities
- GRTS Stock
- News Gritstone bio, Inc.
- Gritstone Oncology : Begins Dosing in Phase 1 Trial of Second-Generation COVID-19 Vaccine